Nuveen
OCUL icon

Nuveen’s Ocular Therapeutix OCUL Stock Holding History

Nuveen’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Buy
1,697,274
+1,286,194
+313% +$11.7M ﹤0.01% 1379
2026
Q1 		$3.48M Sell
411,080
-51,727
-11% -$493K ﹤0.01% 2047
2025
Q4 		$5.62M Buy
462,807
+117,446
+34% +$1.43M ﹤0.01% 1857
2025
Q3 		$4.04M Sell
345,361
-16,949
-5% -$203K ﹤0.01% 2003
2025
Q2 		$3.36M Sell
362,310
-51,794
-13% -$405K ﹤0.01% 2070
2025
Q1 		$3.04M Hold
414,104
– – ﹤0.01% 2155
2024
Q4 		$3.54M Sell
414,104
-88,468
-18% -$863K ﹤0.01% 2138
2024
Q3 		$4.37M Buy
502,572
+85,799
+21% +$707K ﹤0.01% 2051
2024
Q2 		$2.85M Sell
416,773
-796,672
-66% -$4.92M ﹤0.01% 2210
2024
Q1 		$11M Buy
1,213,445
+200,902
+20% +$1.43M ﹤0.01% 1531
2023
Q4 		$4.52M Buy
1,012,543
+1,505
+0.1% +$4.45K ﹤0.01% 2039
2023
Q3 		$3.17M Buy
1,011,038
+91,436
+10% +$374K ﹤0.01% 2094
2023
Q2 		$4.75M Buy
919,602
+726,569
+376% +$4.32M ﹤0.01% 1946
2023
Q1 		$1.02M Sell
193,033
-18,127
-9% -$86.1K ﹤0.01% 2608
2022
Q4 		$594K Sell
211,160
-46,102
-18% -$153K ﹤0.01% 2837
2022
Q3 		$1.07M Sell
257,262
-90,835
-26% -$458K ﹤0.01% 2725
2022
Q2 		$1.4M Buy
348,097
+20,278
+6% +$76.6K ﹤0.01% 2622
2022
Q1 		$1.67M Sell
327,819
-61,729
-16% -$342K ﹤0.01% 2587
2021
Q4 		$2.42M Buy
389,548
+61,028
+19% +$474K ﹤0.01% 2477
2021
Q3 		$3.47M Buy
328,520
+67,812
+26% +$762K ﹤0.01% 2413
2021
Q2 		$3.7M Buy
260,708
+5,757
+2% +$87.5K ﹤0.01% 2402
2021
Q1 		$4.18M Sell
254,951
-345,720
-58% -$6.66M ﹤0.01% 2247
2020
Q4 		$12.4M Buy
600,671
+353,949
+143% +$5.26M ﹤0.01% 1551
2020
Q3 		$1.88M Buy
246,722
+28,488
+13% +$236K ﹤0.01% 2414
2020
Q2 		$1.82M Buy
218,234
+76,485
+54% +$507K ﹤0.01% 2375
2020
Q1 		$701K Buy
141,749
+8,261
+6% +$40.8K ﹤0.01% 2655
2019
Q4 		$527K Sell
133,488
-58,343
-30% -$203K ﹤0.01% 2896
2019
Q3 		$583K Buy
191,831
+65,541
+52% +$293K ﹤0.01% 2892
2019
Q2 		$556K Buy
+126,290
New +$468K ﹤0.01% 2968

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's OCUL Position: Q2 2026 in Review

Nuveen increased its Ocular Therapeutix (OCUL) stake by 313% in Q2 2026, buying an estimated $11.7M and bringing the position to 1,697,274 shares worth $16.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1379.

Nuveen first reported a position in OCUL in Q2 2019 and has held it in 29 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Nuveen held 1,697,274 shares of Ocular Therapeutix worth $16.7M as of Q2 2026.
  • Nuveen bought 1,286,194 Ocular Therapeutix shares in Q2 2026, an estimated $11.7M.
  • Ocular Therapeutix made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1379 holding.
  • Nuveen first reported a position in Ocular Therapeutix in Q2 2019 and has held it in 29 quarters since.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.